20 November 2023

The UK is to have access to its first gene editing therapy for sickle cell disease and β-thalassaemia, it has been announced.

The CRISPR-based treatment, Casgevy, gained a licence from the Medicines and Healthcare products Regulatory Agency (MHRA) last week following a successful trial in the UK.

The treatment – which edits faulty genes in the patient’s bone marrow stem cells – will still need funding and may need assessment from the National Institute for Health and Care Excellence (NICE).

Some 29 sickle cell patients have completed a trial of the treatment – of which all but one reported freedom from severe pain crises for at least 12 months after treatment.

42 patients with β-thalassaemia have completed the trial – and 39 did not receive a red blood cell transfusion for at least 12 months. Researchers say side-effects are similar to those associated with autologous stem cell transplants.

John James, chief executive of the Sickle Cell Society, said: “There are limited medicines currently available to patients, so I welcome today’s news that a new treatment has been judged safe and effective, which has the potential to significantly improve the quality of life for so many.”

Julian Beach, from the MHRA, said: “Both sickle cell disease and β-thalassemia are painful, life-long conditions that in some cases can be fatal. To date, a bone marrow transplant – which must come from a closely matched donor and carries a risk of rejection – has been the only permanent treatment option.  

“I am pleased to announce that we have authorised an innovative and first-of-its-kind gene-editing treatment called Casgevy, which in trials has been found to restore healthy haemoglobin production in the majority of participants with sickle-cell disease and transfusion-dependent β-thalassaemia, relieving the symptoms of disease. 

“The MHRA will continue to closely monitor the safety and effectiveness of Casgevy, through real-world safety data and post-authorisation safety studies being carried out by the manufacturer.”

Source: MHRA


Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News.